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1029-22 Catheter-Based Electromechanical Mapplng to Assess 
Yyocardial Viability: A Comparative Analysis With 
SPECT Radionucllde Perfusion lmaglng 
wKornowski, Shmuel Fuchs, Robert C. Hendel, Martin B. Leon, Rabin Medical Center, 
Petach-Tikva, Israel, Lenox Hi// Hospital, New York, New York. 
Background: Catheter-based assessment of left ventricular (LV) electromechanical activ- 
ity using a non-fluoroscopic 3D mapping may demonstrate variations in electrical and 
mechanical activity within regions of infarction or ischemia. This large-scale study exam- 
ined the correlation between the mapping technique and radionuclide myocardial p&u- 
sion imaging. 
Methods: A 12-segment comparative analysis model was used in 139 patients (96 
males, 63+12 yrs) with refractory angina, having reversible and/or fixed perfusion defects 
on single photon emission computed tomography perfusion (SPECT) imaging. A dual 
isotope protocol was used, consisting of rest thallium-201 followed by adenosine techne- 
tium-99m sestamibi imaging @stress. Average unipolar voltage (UpV) and local shorlen- 
ing (LS) values ware compared with visual-derived perfusion scores and graded on a 0 
(normal) through 4 (absent) activity scale within 1666 segments. 
Results: There was gradual and proportional reduction in regional UpV and LS in relation 
to perfusion score @rest and on adenosine stress (p=O.OOOl and p=O.OOOl, respectively, 
for both comparisons). UpV threshold of ~7.4 mV had sensitivity and specificity of 77% 
and 70% for detecting viable tissue (i.e. perfusion score <2 @rest) with odds and likeli- 
hood ratios of 6.1 and 2.6, respectively. UpV of 11.2 and 5.4 mV had 90% specificity and 
sensitivity, respectively, to predict viable 1issue. Receiver-operating characteristic (ROC) 
curves showed higher sensitivity and specificity for UpV vs. LS value for detecting viabil- 
ity. The area under the curve was greater for rest vs. stress imaging (area under ROC 
curve was 0.60 vs. 0.61 for UpV, pcO.01, 0.71 vs. 0.60 for LLS, ~~0.05). 
Conclusion: Catheter based LV electromechanical mapping correlates well with the scin- 
tigraphic assessment of myocardial viability, especially as determined by resting thallium 
imaging. 
1029-23 Longevity of the Placebo Effect in Patients Enrolled in 
Anglogenesis and Laser Myocardial Revascularixation 
Trials 
wr J. I sham, David J. Cohen. Joseph P. Carrozza, Kalon K. Ho, Ariuna Mannam, 
Frank W. Sellke. B/DMC/Haward Medical School, Boston, Massachusetts. 
Background: The investigation of therapeutic angiogenesis and laser myocardial revas- 
cularization (LMR) with promising initial phase I open label studies and disappointing 
negative phase II randomized double blind studies have underscored the role of the pla- 
cebo effect in this “no-option” patient population. The longevity of this effect, however, 
has not been defined. 
Methods: Patients enrolled in phase I and Phase II angiogenesis and LMR studies (with 
negative primary endpoints) were followed clinically for persistence of the placebo effect 
prior lo disclosure of trial results and treatment assignment. 
Results: A total of 129 patients were so studied. The mean age was 65.4+10 years with 
19 women. 46 (36%) patients had Diabetes MeIIi1us, 40 (31%) had HTN, 112 (67%) had 
prior CABG, and 57 (44%) had prior myocardial infarction. EF was 44*14% (range: 16. 
70%). The mean follow-up was 30+6 months (range: 24-42 months). The mean angina 
class at baseline was 3.Od.5 (CCS) at baseline and improved to 2.1kO.6 at 6 months 
(p<O.OOl) with 24.6% of patients improved by 2 or more angina classes. On long term 
follow-up, 3 patients (2.3%), 3 (2.3%) patients had a QWMI, and 9 patients (6.9%) had 
repeat revasculatization (PTCA). At last follow-up. the angina class was 2.3*0.6 
(p-=0.001 compared to baseline and p=O.O2 compared to 6-month data) and 26.2% of 
patients had persistent improvement in 2 or more angina classes. The improvement in 
Quality of life (SAQ) at 6 months was maintained at last follow-up in 79% of 56 patients 
studied to date. 
Concluelons: The placebo effect observed in many angiogenesis and laser myocardial 
revascularization studies is mostly maintained at 3&S months of follow-up. Thus, its per- 
sistence cannot be used as evidence of efficacy and double-blinded trials are essential in 
this patient population. 
1029-24 Pilot Study Evaluating the Use of Cryoenergy for 
Percutaneous Myocardial Revascularlzatlon 
Richard GallQ, Duncan Stewart, Marc Dubuc, Bradley Strauss. Robert Chisholm, Cezar 
Staniloae, Pierre Theroux, Montreal Heart Institute, Montreal, Ouebec, Canada, St- 
Michael’s Hospital, Toronto, Ontario, Canada. 
Preclinical data in both the canine and porcine model have demonstrated an impressive 
arteriogenic response in cryo-treated myocardium. In a non-randomized phase II study 
we evaluated the safety and efficacy of a percutaneous device in humans. 
Methods: Patients (n=20) suffering from CCS angina class Ill or IV not amenable lo per- 
cutaneous or surgical revascularization ware enrolled. Cryoenergy was delivered using a 
9F catheter with a 4 mm tip electrode (CryoCath Technologies Inc., Montreal, Canada). 
The catheter was advanced retrogradely through the aortic valve. Single two-minute 
cryoapplications ware palformed at 6 lo 6 sites in the lefl ventricle. Study endpoints 
included: safety outcomes immediately after the procedure and at 1 month. Efficacy and- 
points assessed at 6 months included: Angina class (Canadian Cardiovascular Society 
score), quality of life index (Seattle angina questionnaire), exercise stress testing (ACIP 
protocol), and myocardial perfusion (thallium or sesta-mibi nuclear scintigraphy). 
Results: The procedure was performed successfully in 16 of 20 patients. Inability to cross 
a stenotic aortic valve precluded the procedure in one patient. Major complications were 
encountered in only 1 patient. (pericardial tamponade). Preliminary 6-month data is avail- 
able for the first 11 of 20 patients. Angina was improved by al least 1 CCS class in all 
patients and by 2 classes in 64% of patients. The quality of life index was improved in 
76% of patients (pcO.05). Exercise times improved in 72% of patients and increased by 
1.95 * 0.61 minutes (~~0.05) at 6 months. However, no significant changes were 
observed between baseline and 6 month perfusion defects on nuclear scintigraphy. 
Conclusions: Percutaneous catheter delivered cryoenergy appears to be a relatively safe 
procedure. Despite the absence of improvement in myocardial perfusion as assessed by 
nuclear scintigraphy, preliminary results using this technology are encouraging with a 
sustained benefit in total exercise times, quality of life and angina class observed at 6 
months. Results for all 20 patients are pending and will be disclosed forthcomingly. 
1029-25 Adenovirus-Catheter Compatibility Determines Gene 
Expression Following Delivery to Porcine Myocardium 
Wendv A. NW, Bruce D. Klugherz, John J. Lepore, Sloane Guy, Sina Moainie, 
Robert Gorman, Maria Palasis. Robert L. Wilensky, University of Pennsylvania, 
Philadelphia, Pennsylvania, Boston Scientific Corporation, Natick, Massachusetts. 
Background: Endomyocardial injection of adenoviral gene therapies enables localized 
delivery lo compromised myocardial 1issue. In cell culture we have shown that many 
materials used in endomyocardial delivery catheters are not compatible with adenoviral 
gene vectors. resulting in up to 90% reduction in virus activity. In this study, we assessed 
catheter-adenovirus compatibility in an in viva model. 
Methods: In an open chest pig model, using the LAD and LCX as boundaries, the ante- 
rolateral epicardial surface was divided into basal and apical regions. A nitinol-stainless 
steel injection catheter (Ni-SS catheter), or a catheter with a Modified lumen was used to 
deliver adenovirus (5 injections of 10 ul AdCMV-LacZ, 5~10~ IUiml). To minimize variabil- 
ity, both devices were used in each animal and the injection sequence randomized. Ani- 
mals (n=4) were sacrificed 3 days post-procedure and the injection zones were 
dissected. The tissue was homogenized and assayed for P-gal activity and total protein. 
Results: Regional p-gal activity expressed as total relative light units (RLU) normalized 
lo total extracted protein was increased in all zones delivered with the Modified catheter. 
Conclusions: Fundamental material-virus interactions directly determine efficiency of 
adenovirus-mediated gene expression in myocardium. These data have important impli- 
cations for percutaneous myccardial gene delivery. 
P-Galaclosidase Activity 
(RLUlmg protein x 105) 
Animal Ni-SS Catheter 
1 1 
2 22 
3 0.2 
4 30 
Modified Catheter 
17 
450 
43 
175 
1029-26 Transmyocardial Laser Revascularixatlon and AdVEGF- 
Transfection Promotes Angiogenesls in lschemic 
Myocardium 
Richard, Michael Hsin, Tom Are& Massachusetts General Hospital, Boston, 
Massachusetts, Brigham and Womens Hospital, Boston, Massachusetts. 
Background: The mechanism of transmyocardial laser revascularization (TMR) is 
unclear. To evaluate the morphologic changes and long-term effects of TMR in chronic 
ischemia we analyzed vascular density in collateral-dependent myocardium 6 months 
follwing TMR and/or VEGF transfection. 
Methods: An Ameroid constrictor was placed around the left circumflex in 31 pigs. The 
TMR group (n=9) underwent TMR of the I& circumflex territory 6 weeks post-Ameroid. 
The control group (n=6) had Ameriods without TMR or no operation at all (n=5) or Aden- 
ovirus promoted vascular endothelial growth factor (AdVEGF)-transfection. n=6). or com- 
bined TMR and AdVEGF-transfection (n=5). Histopathological evaluation by 
morphomatric analysis (IP Lab Spectrum) at 40x and 200x magnification was performed 
on H&E, CD31. van Willebrand and Anti-VEGF (~~157) stained transmural sections. 
Results: Number of vessels (N), vascular density expressed as vascular area (A) and 
area per vessel (AIN) were measured in the endocardial and epicardial region. Vessel 
count and vascular density of small vessels (diameter < 500 urn) was higher in the 
endocardial region compared to the epicardial region (N=34+11 vs. N=22+9, p 700 urn) 
were more frequent in the epicardial region compared to the endocardial region and had 
a higher vascular density (A/N=0.53+0.25 vs. 0.44+0.26, p<O.O05). This finding was seen 
in the TMR group as well as in the controls. In the TMR group, a high vascular density 
was found in and surrounding the TMR channels compared to myocardium of the same 
hearts in more than 2 cm distance to the channels (A/N= 0.66+0.31 vs. 0.49+0.24, 
p<O.OOl). AdVEGF-transfected endocardial sections revealed A/N= 0.72+0.26 (n.s.), and 
A/N= 0.95+0.24 (p<O.Ol) with combined TMR and AdVEGF-transfection. 
Conclusions: These data suggest that TMR promotes angiogenesis at the site of Inter- 
vention in chronic myocatdial ischemia. Combinations with growth factors such as VEGF 
could enhance this angiogenetic effect. 
